Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 173
Filter
1.
Neurotherapeutics ; 20(3): 633-654, 2023 Apr.
Article in English | MEDLINE | ID: mdl-37072548

ABSTRACT

Though rare, stroke in infants and children is an important cause of mortality and chronic morbidity in the pediatric population. Neuroimaging advances and implementation of pediatric stroke care protocols have led to the ability to rapidly diagnose stroke and in many cases determine the stroke etiology. Though data on efficacy of hyperacute therapies, such as intravenous thrombolysis and mechanical thrombectomy, in pediatric stroke are limited, feasibility and safety data are mounting and support careful consideration of these treatments for childhood stroke. Recent therapeutic advances allow for targeted stroke prevention efforts in high-risk conditions, such as moyamoya, sickle cell disease, cardiac disease, and genetic disorders. Despite these exciting advances, important knowledge gaps persist, including optimal dosing and type of thrombolytic agents, inclusion criteria for mechanical thrombectomy, the role of immunomodulatory therapies for focal cerebral arteriopathy, optimal long-term antithrombotic strategies, the role of patent foramen ovale closure in pediatric stroke, and optimal rehabilitation strategies after stroke of the developing brain.


Subject(s)
Cerebral Arterial Diseases , Ischemic Stroke , Child , Humans , Cerebral Arterial Diseases/complications , Cerebral Arterial Diseases/diagnosis , Cerebral Arterial Diseases/drug therapy , Cerebral Arterial Diseases/therapy , Fibrinolytic Agents/administration & dosage , Fibrinolytic Agents/therapeutic use , Heart Diseases/complications , Hematologic Diseases/complications , Infections/complications , Ischemic Stroke/diagnosis , Ischemic Stroke/etiology , Ischemic Stroke/rehabilitation , Ischemic Stroke/therapy , Neoplasms/complications , Thrombolytic Therapy , Mechanical Thrombolysis
2.
Semin Pediatr Neurol ; 43: 101004, 2022 10.
Article in English | MEDLINE | ID: mdl-36344018

ABSTRACT

Up to more than half of previously healthy children presenting with their first arterial ischemic stroke have a cerebral arteriopathy. Cerebral arteriopathies during childhood can be congenital, reflecting abnormal vessel development, or acquired when caused by disruption of vascular homeostasis. Distinguishing different types of cerebral arteriopathies in children can be challenging but of great clinical value as they may dictate different disease and treatment courses, and clinical and radiologic outcomes. Furthermore, children with stroke due to a specific arteriopathy exhibit distinctive features when compared to those with stroke due to other causes or a different type of arteriopathy. These features become crucial in the management of pediatric stroke by choosing appropriate diagnostic and treatment strategies. The objective of this article is to provide the reader with a comprehensive up-to-date review of the classification, symptoms, diagnosis, treatment, and outcome of cerebral arteriopathies in children.


Subject(s)
Cerebral Arterial Diseases , Cerebrovascular Disorders , Stroke , Child , Humans , Cerebral Arterial Diseases/diagnosis , Cerebral Arterial Diseases/therapy , Cerebral Arterial Diseases/complications , Stroke/diagnosis , Stroke/etiology , Stroke/therapy
3.
Eur J Radiol ; 142: 109846, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34247031

ABSTRACT

Acute ischaemic stroke (AIS) in children is generally considered an up-to-date and controversial topic because its presents significant peculiarities. Focal cerebral arteriopathies (FCA) are a possible cause of AIS in children characterized by an unilateral lesion of the terminal internal cerebral artery (ICA) and proximal segment (M1) of middle cerebral artery (MCA), leading to subocclusion, occasionally with a typical "striate" pattern and a tendency to stability or regression at follow-up. It is unclear whether in FCA the basic lesion is an inflammatory or a dissective arterial pathology. Herein we report a small series of children (<16 yo) with AIS from a FCA who underwent mechanical thrombectomy (MT). We speculate on the angiographic findings suggesting an aetiology of the lesion, and on indications and limits of the currently available treatments.


Subject(s)
Brain Ischemia , Cerebral Arterial Diseases , Cerebrovascular Disorders , Ischemic Stroke , Stroke , Brain Ischemia/diagnostic imaging , Cerebral Arterial Diseases/diagnostic imaging , Cerebral Arterial Diseases/therapy , Child , Humans , Middle Cerebral Artery , Stroke/diagnostic imaging , Stroke/therapy , Thrombectomy , Treatment Outcome
4.
Lancet Child Adolesc Health ; 5(11): 825-836, 2021 11.
Article in English | MEDLINE | ID: mdl-34331864

ABSTRACT

Paediatric arterial ischaemic stroke is an important cause of neurological morbidity in children, with consequences including motor disorders, intellectual impairment, and epilepsy. The causes of paediatric arterial ischaemic stroke are unique compared with those associated with stroke in adulthood. The past decade has seen substantial advances in paediatric stroke research and clinical care, but many unanswered questions and controversies remain. Shortage of prospective evidence for the use of recanalisation therapies in patients with paediatric stroke has resulted in little standardisation of disease management. Substantial time delays in diagnosis and treatment continue to challenge best possible care. In this Review, we highlight on some of the most pressing and productive aspects of research in the treatment of arterial ischaemic stroke in children, including epidemiology and cause, rehabilitation, secondary stroke prevention, and treatment updates focusing on advances in hyperacute therapies such as intravenous thrombolysis, mechanical thrombectomy, and critical care. Finally, we provide a future perspective for improving outcomes and quality of life for affected children and their families.


Subject(s)
Brain Ischemia/therapy , Cerebral Arterial Diseases/therapy , Ischemic Stroke/therapy , Adolescent , Brain Ischemia/epidemiology , Brain Ischemia/prevention & control , Brain Ischemia/rehabilitation , Cerebral Arterial Diseases/epidemiology , Cerebral Arterial Diseases/prevention & control , Cerebral Arterial Diseases/rehabilitation , Child , Child, Preschool , Humans , Infant , Ischemic Stroke/epidemiology , Ischemic Stroke/prevention & control , Ischemic Stroke/rehabilitation
5.
Neurology ; 96(23): e2839-e2853, 2021 06 08.
Article in English | MEDLINE | ID: mdl-33875560

ABSTRACT

OBJECTIVE: To evaluate the comparative safety and efficacy of direct endovascular thrombectomy (dEVT) compared to bridging therapy (BT; IV tissue plasminogen activator + EVT) and to assess whether BT potential benefit relates to stroke severity, size, and initial presentation to EVT vs non-EVT center. METHODS: In a prospective multicenter cohort study of imaging selection for endovascular thrombectomy (Optimizing Patient Selection for Endovascular Treatment in Acute Ischemic Stroke [SELECT]), patients with anterior circulation large vessel occlusion (LVO) presenting to EVT-capable centers within 4.5 hours from last known well were stratified into BT vs dEVT. The primary outcome was 90-day functional independence (modified Rankin Scale [mRS] score 0-2). Secondary outcomes included a shift across 90-day mRS grades, mortality, and symptomatic intracranial hemorrhage. We also performed subgroup analyses according to initial presentation to EVT-capable center (direct vs transfer), stroke severity, and baseline infarct core volume. RESULTS: We identified 226 LVOs (54% men, mean age 65.6 ± 14.6 years, median NIH Stroke Scale [NIHSS] score 17, 28% received dEVT). Median time from arrival to groin puncture did not differ in patients with BT when presenting directly (dEVT 1.43 [interquartile range (IQR) 1.13-1.90] hours vs BT 1.58 [IQR 1.27-2.02] hours, p = 0.40) or transferred to EVT-capable centers (dEVT 1.17 [IQR 0.90-1.48] hours vs BT 1.27 [IQR 0.97-1.87] hours, p = 0.24). BT was associated with higher odds of 90-day functional independence (57% vs 44%, adjusted odds ratio [aOR] 2.02, 95% confidence interval [CI] 1.01-4.03, p = 0.046) and functional improvement (adjusted common OR 2.06, 95% CI 1.18-3.60, p = 0.011) and lower likelihood of 90-day mortality (11% vs 23%, aOR 0.20, 95% CI 0.07-0.58, p = 0.003). No differences in any other outcomes were detected. In subgroup analyses, patients with BT with baseline NIHSS scores <15 had higher functional independence likelihood compared to those with dEVT (aOR 4.87, 95% CI 1.56-15.18, p = 0.006); this association was not evident for patients with NIHSS scores ≥15 (aOR 1.05, 95% CI 0.40-2.74, p = 0.92). Similarly, functional outcomes improvements with BT were detected in patients with core volume strata (ischemic core <50 cm3: aOR 2.10, 95% CI 1.02-4.33, p = 0.044 vs ischemic core ≥50 cm3: aOR 0.41, 95% CI 0.01-16.02, p = 0.64) and transfer status (transferred: aOR 2.21, 95% CI 0.93-9.65, p = 0.29 vs direct to EVT center: aOR 1.84, 95% CI 0.80-4.23, p = 0.15). CONCLUSIONS: BT appears to be associated with better clinical outcomes, especially with milder NIHSS scores, smaller presentation core volumes, and those who were "dripped and shipped." We did not observe any potential benefit of BT in patients with more severe strokes. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Identifier: NCT02446587. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for patients with ischemic stroke from anterior circulation LVO within 4.5 hours from last known well, BT compared to dEVT leads to better 90-day functional outcomes.


Subject(s)
Arterial Occlusive Diseases/therapy , Cerebral Arterial Diseases/therapy , Fibrinolytic Agents/administration & dosage , Ischemic Stroke/therapy , Outcome Assessment, Health Care/statistics & numerical data , Thrombectomy/statistics & numerical data , Time-to-Treatment/statistics & numerical data , Tissue Plasminogen Activator/administration & dosage , Aged , Aged, 80 and over , Arterial Occlusive Diseases/drug therapy , Cerebral Arterial Diseases/drug therapy , Cohort Studies , Female , Humans , Ischemic Stroke/drug therapy , Male , Middle Aged
6.
Zhonghua Wai Ke Za Zhi ; 59(3): 203-209, 2021 Mar 01.
Article in Chinese | MEDLINE | ID: mdl-33685054

ABSTRACT

Objective: To investigate the efficacy and the safety of intravascular therapy for cerebrovascular ischemic tandem stenosis. Methods: Clinical data of 35 patients with symptomatic anterior circulation and posterior circulation tandem stenosis who received intravascular therapy for two sites of stenosis at the same time at Department of Neurosurgery of Peking University First Hospital from January 2013 to December 2018 were analyzed retrospectively. There were 27 males and 8 females,aged (65.6±9.4)years (range:47 to 81 years).There were 14 cases of anterior circulation tandem stenosis and 21 of posterior circulation tandem stenosis.The medical records were collected with emphasis on postoperative symptoms,imaging manifestations and modified Rankin scale(mRS) scores. Results: Sixty-eight stents were implants in to 35 patients,including 49 extracranial implants and 19 intracranial implants.The surgical success rate was 100%.The perioperative death rate was 0,and 1 patient(1/35,2.9%) had cerebral hemorrhage.All patients were followed up for 18 months.During 3 to 12 months after the intervention,1 case(1/35,2.9%) had stent restenosis,and 4 cases(4/35,11.4%) had persisted symptoms such as dizziness and weakness in limbs.All patients'mRS scores were ≤2. No new stroke occurred. During 12 to 18 months after the intervention,3 cases had in-stent restenosis,increasing the rate to 11.4% (4/35). The mRS scores of 32 patients(32/35,91.4%) were ≤2. Conclusion: Intravascular therapy for patients with symptomatic tandem stenosis is a feasible and safe procedure with good short-term outcomes.


Subject(s)
Brain Ischemia/therapy , Cerebral Arterial Diseases/therapy , Constriction, Pathologic/therapy , Endovascular Procedures , Stents , Aged , Aged, 80 and over , Blood Vessel Prosthesis Implantation , Brain Ischemia/etiology , Endovascular Procedures/instrumentation , Endovascular Procedures/methods , Female , Humans , Male , Middle Aged , Retrospective Studies , Treatment Outcome
7.
Neurology ; 95(24): e3364-e3372, 2020 12 15.
Article in English | MEDLINE | ID: mdl-32989100

ABSTRACT

OBJECTIVE: To undertake an effectiveness and safety analysis of EVT in patients with LVO and NIH Stroke Scale (NIHSS) score ≤6 using datasets of multicenter and multinational nature. METHODS: We pooled patients with anterior circulation occlusion from 3 prospective international cohorts. Patients were eligible if presentation occurred within 12 hours from last known well and baseline NIHSS ≤6. Primary outcome was modified Rankin Scale (mRS) score 0-1 at 90 days. Secondary outcomes included neurologic deterioration at 24 hours (change in NIHSS of ≥2 points), mRS 0-2 at 90 days, and 90-day all-cause mortality. We used propensity score matching to adjust for nonrandomized treatment allocation. RESULTS: Among 236 patients who fit inclusion criteria, 139 received EVT and 97 received medical management. Compared to medical management, the EVT group was younger (65 vs 72 years; p < 0.001), had more proximal occlusions (p < 0.001), and less frequently received concurrent IV thrombolysis (57.7% vs 71.2%; p = 0.04). After propensity score matching, clinical outcomes between the 2 groups were not significantly different. EVT patients had an 8.6% (95% confidence interval [CI] -8.8% to 26.1%) higher rate of excellent 90-day outcome, despite a 22.3% (95% CI, 3.0%-41.6%) higher risk of neurologic deterioration at 24 hours. CONCLUSIONS: EVT for LVO in patients with low NIHSS score was associated with increased risk of neurologic deterioration at 24 hours. However, both EVT and medical management resulted in similar proportions of excellent clinical outcomes at 90 days. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for patients with acute anterior circulation ischemic strokes and LVO with NIHSS < 6, EVT and medical management result in similar outcomes at 90 days.


Subject(s)
Disease Progression , Endovascular Procedures , Fibrinolytic Agents/administration & dosage , Ischemic Stroke/therapy , Outcome Assessment, Health Care , Registries , Severity of Illness Index , Thrombectomy , Aged , Aged, 80 and over , Arterial Occlusive Diseases/therapy , Cerebral Arterial Diseases/therapy , Endovascular Procedures/statistics & numerical data , Female , Follow-Up Studies , Humans , Ischemic Stroke/drug therapy , Male , Middle Aged , Outcome Assessment, Health Care/statistics & numerical data , Thrombectomy/statistics & numerical data
8.
J Neurol ; 267(6): 1651-1662, 2020 Jun.
Article in English | MEDLINE | ID: mdl-32062782

ABSTRACT

BACKGROUND: Optimal management of patients with large vessel occlusion (LVO) and low NIHSS score is unknown, which was the aim to investigate in this study. METHODS: This is a retrospective analysis of a prospective single tertiary care centre 14-year cohort of patients with LVO in the anterior circulation and NIHSS score ≤ 5 on admission. Outcome was analysed according to primary intended therapy. RESULTS: Among 185 patients (median age 67.4 years), 52.4% received primary conservative therapy (including 26.8% secondary reperfusion in case of secondary neurological deterioration), 12.4% IV thrombolysis (IVT) only and 35.1% primary endovascular therapy (EVT). 95 (51.4%) patients experienced neurological deterioration until 3 months. Primary-IVT-only and primary-EVT compared to conservative-therapy patients had better 3 months' outcome (54.5% vs. 30.8%: adjustedOR 6.02; adjustedp = 0.004 for mRS 0-1 and 54.7% vs. 30.8%: adjustedOR 5.09; adjustedp = 0.002, respectively). Also mRS shift analysis favored primary-IVT-only and primary-EVT patients (adjustedOR 6.25; adjustedp = 0.001 and adjustedOR 3.14; adjustedp = 0.003). Outcome in primary-IVT-only vs. primary-EVT patients did not differ significantly. Patients who received secondary EVT because of neurological deterioration after primary-conservative-therapy had worse 3 months' outcome than primary-EVT patients (20.8% vs. 30.8%: adjustedOR 0.24; adjustedp = 0.047 for mRS 0-1 and adjustedOR 0.31; adjustedp = 0.019 in mRS shift analysis). Survival and symptomatic intracranial haemorrhage did not differ amongst groups. CONCLUSIONS: Our data indicate that primary IVT and/or EVT may be better than primary conservative therapy in patients with LVO in the anterior circulation and low NIHSS score. Furthermore, primary EVT was better than secondary EVT in case of neurological deterioration. There is an unmet need for RCTs to find the optimal therapy for this patient group.


Subject(s)
Arterial Occlusive Diseases/therapy , Cerebral Arterial Diseases/therapy , Endovascular Procedures , Fibrinolytic Agents/pharmacology , Outcome Assessment, Health Care , Severity of Illness Index , Adult , Aged , Aged, 80 and over , Arterial Occlusive Diseases/drug therapy , Cerebral Arterial Diseases/drug therapy , Female , Fibrinolytic Agents/administration & dosage , Humans , Male , Middle Aged , Prospective Studies , Retrospective Studies , Tertiary Care Centers
9.
Rev Neurol (Paris) ; 176(1-2): 20-29, 2020.
Article in English | MEDLINE | ID: mdl-31182310

ABSTRACT

Pediatric arterial ischemic stroke (AIS) is a severe condition, with long-lasting devastating consequences on motor and cognitive abilities, academic and social inclusion, and global life projects. Awareness about initial symptoms, implementation of pediatric stroke code protocols using MRI first and only and adapted management in the acute phase, individually tailored recanalization treatment strategies, and multidisciplinary rehabilitation programs with specific goal-centered actions are the key elements to improve pediatric AIS management and outcomes. The main cause of pediatric AIS is focal cerebral arteriopathy, a condition with unilateral focal stenosis and time-limited course requiring specific management. Sickle cell disease and moyamoya angiopathy patients need adapted screening and therapeutics.


Subject(s)
Cerebral Arterial Diseases/diagnosis , Cerebral Arterial Diseases/therapy , Pediatrics/methods , Stroke/diagnosis , Stroke/therapy , Age of Onset , Brain Ischemia/diagnosis , Brain Ischemia/epidemiology , Brain Ischemia/therapy , Cerebral Arterial Diseases/epidemiology , Child , Humans , Stroke/epidemiology
10.
J Neuroradiol ; 47(4): 301-305, 2020 Jun.
Article in English | MEDLINE | ID: mdl-30951765

ABSTRACT

BACKGROUND AND PURPOSE: The NeVa™ (Vesalio, Nashville, Tennessee) thrombectomy device is a CE-approved novel hybrid-cell stent retriever with offset enlarged openings coupled with functional zones and a closed distal end. The device was designed to incorporate and trap resistant emboli. The purpose was to determine the safety and efficacy of the NeVa™ stent. METHODS: Prospective data was collected on the first thirty consecutive patients treated at four stroke centers with NeVa™ as first line treatment between December 2017 and May 2018. Clinical outcome measures included re-perfusion scores after each pass, complications (per-procedural complications, device related adverse events, all intracerebral hemorrhage (ICH) and symptomatic ICH (sICH) on follow up imaging), 24 hour NIHSS, mRS at discharge and 90 days. Baseline data as well as treatment parameters were documented. RESULTS: Mean presenting NIHSS was 16. Sites of primary occlusion were 10 ICA, 16 M1-MCA, 3 M2-MCA and one basilar. There were five tandem occlusions. Reperfusion outcomes after each NeVa pass; TICI ≥ 2b after first pass 63%, after 1 or 2 passes 83%, after 1 to 3 passes 90%. TICI 2c-3 after first pass 47%, after 1-2 passes 57%, after 1-3 passes 60%. TICI ≥ 2b after final pass 93%; TICI 2c-3, 63%. There were no device related serious averse events and no sICH. Clot material was partially or completely incorporated into the device after 70% passes. The mean 24 hour NIHSS was 7 and the 90 day mRS was 0-2 in 53%. CONCLUSIONS: The NeVa™ device demonstrated a high rate of first pass complete reperfusion effect, a good safety profile and favorable 90 day clinical outcomes in this initial clinical experience.


Subject(s)
Cerebral Arterial Diseases/therapy , Cerebral Hemorrhage/therapy , Mechanical Thrombolysis/instrumentation , Mechanical Thrombolysis/methods , Stents , Stroke/therapy , Aged , Cerebral Arterial Diseases/complications , Cerebral Hemorrhage/complications , Female , Humans , Male , Prospective Studies , Stroke/complications , Treatment Outcome
11.
J Neurol ; 267(4): 1026-1034, 2020 Apr.
Article in English | MEDLINE | ID: mdl-31834520

ABSTRACT

BACKGROUND AND PURPOSE: Mechanical thrombectomy (MT) improves early clinical outcome in patients with acute ischemic stroke but insights on determinants of long-term outcome after MT treatment are scarce. METHODS: Data from stroke patients with anterior circulation large vessel occlusion of a prospective MT registry (01/2014-06/2017) of a large comprehensive stroke center were analyzed regarding clinical outcome between short- (3 months) and long-term (12 months) assessment reflected by a change of modified Rankin scores (∆mRS). Secondary endpoints included favorable long-term outcome (mRS 0-2). Multi-variable regression analysis was performed to identify determinants of outcome changes and favorable outcome at long term. RESULTS: Of 264 patients included, 42.0% showed a favorable long-term outcome. Longitudinal analysis found that some individuals still improved, but no overall mRS difference between short and long-term follow-up was detected [∆mRS - 0.004 (95% CI - 0.020; 0.013); p = 0.672]. Right hemispheric stroke [∆mRS 0.286 (0.011; 0.561); p = 0.043] and high NIHSS at discharge [∆mRS, 0.039 (0.004; 0.074); p = 0.029] were associated with a longitudinal mRS decline. Favorable long-term outcome was associated with successful recanalization (p < 0.0001). CONCLUSIONS: A significant number of patients with MT experience a favorable long-term outcome. Outcomes remained stable between short- and long-term follow-up, but some individuals may still show improvement beyond short-term rehabilitation. Right hemispheric stroke and clinical stroke severity at hospital discharge may be frail predictors for delayed decline of functional status, whereas successful recanalization remains a positive outcome predictor. Death rarely occurs beyond 3 months after MT treatment.


Subject(s)
Cerebral Arterial Diseases/therapy , Ischemic Stroke/therapy , Mechanical Thrombolysis/statistics & numerical data , Outcome Assessment, Health Care/statistics & numerical data , Registries , Aged , Aged, 80 and over , Cerebral Arterial Diseases/complications , Female , Humans , Ischemic Stroke/etiology , Longitudinal Studies , Male , Middle Aged
12.
Stroke ; 50(7): 1915-1918, 2019 07.
Article in English | MEDLINE | ID: mdl-31167622

ABSTRACT

Background and Purpose- Sex differences in the management and outcomes of acute ischemic stroke with large vessel occlusion are unknown in the era of endovascular therapy (EVT). This study investigated these differences in the RESCUE (Recovery by Endovascular Salvage for Cerebral Ultra-Acute Embolism)-Japan Registry 2 patient database. Methods- RESCUE-Japan Registry 2 registered patients with large vessel occlusion who were admitted within 24 hours of onset were enrolled in this study. We estimated the likelihood to receive EVT according to sex. The primary outcome was good outcome defined as a modified Rankin Scale score of 0 to 2 at 90 days after onset. Secondary outcomes were mortality within 90 days, any or symptomatic intracranial hemorrhage within 72 hours, and recurrence of stroke or transient ischemic attack within 90 days. Results- Among 2399 patients, 1087 patients were female and 1312 were male; 47.9% of females and 57.7% of males received EVT (adjusted odds ratio, 0.71; 95% CI, 0.59-0.86). Good outcome was observed in 27.3% and 44.2% of the females and males, respectively ( P<0.0001). The adjusted odds ratio of a good outcome in females was 0.80 (95% CI, 0.65-0.99). Mortality was 12.3% and 9.9% in females and males, respectively ( P=0.06); the adjusted odds ratio was 0.78 (95% CI, 0.58-1.05). Conclusions- Females with acute ischemic stroke with large vessel occlusion showed poor functional outcome compared to males. Females were less likely to receive EVT; lower utilization of EVT accounted for a portion of the poor outcome.


Subject(s)
Brain Ischemia/therapy , Cerebral Arterial Diseases/therapy , Stroke/therapy , Adult , Age Factors , Aged , Aged, 80 and over , Brain Ischemia/pathology , Cerebral Arterial Diseases/pathology , Databases, Factual , Endovascular Procedures/statistics & numerical data , Female , Humans , Japan/epidemiology , Male , Middle Aged , Prospective Studies , Recovery of Function , Registries , Salvage Therapy , Sex Factors , Stroke/epidemiology , Stroke/pathology , Thrombolytic Therapy , Treatment Outcome
13.
Neurol Med Chir (Tokyo) ; 59(8): 305-312, 2019 Aug 15.
Article in English | MEDLINE | ID: mdl-31130572

ABSTRACT

Japan has a rapidly aging population and the application of neuroendovascular therapy (NET) for cerebrovascular diseases among elderly patients has increased, but feasibility and safety of NET for elderly patients are still debated. Therefore, this study aimed to elucidate feasibility and safety of NET by analyzing the Japanese nationwide database, the Japanese Registry of Neuroendovascular Therapy 3 (JR-NET 3). In total, 35,972 patients in the JR-NET 3 were analyzed retrospectively. "Elderly patients" were defined as those aged ≥75 years. Approximately one-quarter of patients who received NET were elderly patients. The proportion of patients with modified Rankin Scale (mRS) 0-2 before treatment and 30 days after NET was significantly low across all diseases in the elderly patients. Technical success rates were generally high across all procedures, but complication rate was significantly higher among elderly patients; ischemic complications were significantly higher with NET for unruptured aneurysms (UA) and carotid artery stenosis (CAS). Multivariate analysis revealed that mRS 0-2 before treatment [odds ratio (OR): 0.56, 95% confidence interval (CI): 0.34-0.94, P = 0.03], middle cerebral artery aneurysm (OR: 0.33, 95% CI: 0.12-0.92, P = 0.04), and complete obliteration (OR: 0.66, 95% CI: 0.44-0.97, P = 0.03) were associated with ischemic complications with NET for UA. Moreover, mRS 0-2 before treatment (OR: 0.55, 95% CI: 0.36-0.86, P < 0.01), high intensity with time-of-flight magnetic resonance angiography (OR: 1.55, 95% CI: 1.03-2.32, P = 0.04), open-cell stent (OR: 2.20, 95% CI: 1.50-3.22, P <0.01) were associated with ischemic complications with NET for CAS. Taken together, our findings indicate that cautious and precise selection of patients suitable for NET is necessary.


Subject(s)
Cerebrovascular Disorders/therapy , Endovascular Procedures , Patient Safety , Registries , Aged , Aged, 80 and over , Aneurysm, Ruptured/therapy , Carotid Stenosis/therapy , Cerebral Arterial Diseases/therapy , Constriction, Pathologic/therapy , Embolization, Therapeutic , Feasibility Studies , Female , Follow-Up Studies , Humans , Intracranial Aneurysm/therapy , Japan , Male , Middle Aged , Neurologic Examination , Stroke/therapy , Treatment Outcome
14.
Medicine (Baltimore) ; 98(18): e15437, 2019 May.
Article in English | MEDLINE | ID: mdl-31045810

ABSTRACT

RATIONALE: Cranial arterial air embolism is a rare but potentially fatal complication after computed tomography (CT)-guided pulmonary interventions. PATIENT CONCERNS: A 64-year-old man was diagnosed with a pulmonary nodule (diameter: approximately 1 cm) in the right lower lobe. The patient developed convulsions after CT-guided hook-wire localization. DIAGNOSIS: Cranial CT revealed arborizing/linearly distributed gas in the territory of the right middle cerebral artery. INTERVENTIONS: The patient was administered hyperbaric oxygen, antiplatelet aggregation therapy, and dehydration treatment. OUTCOMES: Clinical death occurred 55 hours after air embolism. LESSONS: Systemic air embolism is a serious complication of lung puncture. Clinicians should improve their understanding of this complication and remain vigilant against air embolism.


Subject(s)
Cerebral Arterial Diseases/etiology , Embolism, Air/etiology , Radiography, Interventional/adverse effects , Solitary Pulmonary Nodule/surgery , Cerebral Arterial Diseases/therapy , Embolism, Air/therapy , Humans , Hyperbaric Oxygenation/methods , Male , Middle Aged , Platelet Aggregation Inhibitors/therapeutic use , Radiography, Interventional/methods
15.
J Stroke Cerebrovasc Dis ; 28(7): 1886-1890, 2019 Jul.
Article in English | MEDLINE | ID: mdl-31078387

ABSTRACT

OBJECTIVE: To summarize the characteristics of and therapeutic options for cancer patients whose treatments may be vasotoxic and cause intracranial arterial stenotic disease and stroke. METHODS: We describe 3 patients with symptomatic cerebrovascular pathology that were being actively treated for cancer. RESULTS: Two of the patients were being treated with tyrosine kinase inhibitors (TKIs); and the third was being treated with 2 monoclonal antibodies, one of which was targeting an endothelial growth factor. These agents have been associated with vascular adverse events. Surgical revascularization was done in the first 2 patients, as they were suffering from cerebral ischemia. The third patient had suffered a significant brain hemorrhage, and therapeutic options were limited. In the first 2 patients, treatments also included antiplatelet agents and stopping/changing the TKI. In one of these patients we demonstrated regression of arterial stenosis after changing the TKI. CONCLUSIONS: Possibilities for treatment in this population, beyond the usual medical and surgical administrations, may include stopping or changing cancer drugs that may be related to the development of arterial pathology. Collaboration with oncologists is essential in this subset of patients. While aware of the potential for vascular toxicity, oncologists are often not fully appreciative of the fact that their therapeutic agents can cause stroke.


Subject(s)
Antibodies, Monoclonal/adverse effects , Antineoplastic Agents, Immunological/adverse effects , Arterial Occlusive Diseases/therapy , Cerebral Arterial Diseases/therapy , Cerebral Arteries/surgery , Cerebral Revascularization/methods , Protein Kinase Inhibitors/adverse effects , Aged, 80 and over , Arterial Occlusive Diseases/chemically induced , Arterial Occlusive Diseases/diagnostic imaging , Arterial Occlusive Diseases/physiopathology , Cerebral Angiography/methods , Cerebral Arterial Diseases/chemically induced , Cerebral Arterial Diseases/diagnostic imaging , Cerebral Arterial Diseases/physiopathology , Cerebral Arteries/diagnostic imaging , Cerebral Arteries/drug effects , Cerebral Arteries/physiopathology , Cerebrovascular Circulation , Computed Tomography Angiography , Conservative Treatment , Constriction, Pathologic , Drug Substitution , Fatal Outcome , Female , Humans , Male , Middle Aged , Perfusion Imaging/methods , Platelet Aggregation Inhibitors/therapeutic use , Treatment Outcome , Vascular Patency
17.
Ann Vasc Surg ; 58: 338-346, 2019 Jul.
Article in English | MEDLINE | ID: mdl-30769077

ABSTRACT

BACKGROUND: The aims of this study were to explore (i) the dynamic changes in cerebral microbleeds (CMBs) in patients with symptomatic cerebral artery stenosis who received endovascular stent-assisted angioplasty and (ii) the risk factors associated with the new incidence of CMBs as well as whether CMBs increased the risk of vascular events in these patients. METHODS: Clinical information and magnetic resonance images were collected on admission and 3 months after endovascular stent-assisted angioplasty. Based on susceptibility-weighted imaging, the patients were divided into groups with or without newly developed CMBs, and between-group differences in risk factors were compared. We also compared whether CMBs increased the risk of vascular events among those patients. RESULTS: Seventy-three patients completed the relevant follow-up examinations. After an average follow-up period of 109 days, 7 (9.6%) patients showed new CMBs. A univariate analysis showed that the number of lacunar infarcts and the increase in systolic blood pressure were higher in patients with new CMBs than in those without new CMBs, and these differences were significant (P = 0.034, P = 0.001). Increased systolic blood pressure was an independent risk factor for developing new CMBs (P = 0.017). CONCLUSIONS: CMBs may be a continuously progressing cerebral small-vessel disease. The newly developed CMBs in patients with intracranial and/or extracranial stents were associated with increased systolic blood pressure but not with the number of baseline CMBs.


Subject(s)
Angioplasty/instrumentation , Cerebral Arterial Diseases/therapy , Cerebral Hemorrhage/etiology , Cerebral Small Vessel Diseases/therapy , Stents , Aged , Angiography, Digital Subtraction , Angioplasty/adverse effects , Blood Pressure , Cerebral Angiography/methods , Cerebral Arterial Diseases/complications , Cerebral Arterial Diseases/diagnostic imaging , Cerebral Arterial Diseases/physiopathology , Cerebral Hemorrhage/diagnostic imaging , Cerebral Hemorrhage/physiopathology , Cerebral Small Vessel Diseases/complications , Cerebral Small Vessel Diseases/diagnostic imaging , Cerebral Small Vessel Diseases/physiopathology , Diffusion Magnetic Resonance Imaging , Female , Follow-Up Studies , Humans , Male , Middle Aged , Risk Assessment , Risk Factors , Systole , Time Factors , Treatment Outcome
18.
J Stroke Cerebrovasc Dis ; 28(4): 929-934, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30638942

ABSTRACT

BACKGROUND: With newly-extended treatment windows for endovascular therapy in emergent large vessel occlusions, it is increasingly important to identify thrombectomy-eligible patients without overwhelming resources dedicated to acute stroke care. We devised a simple paradigm to classify patient's presenting neurologic symptoms to screen for large vessel occlusions. METHODS: We reviewed the presenting symptoms, imaging findings, and final diagnoses of consecutive emergency department stroke alert cases. Patients were classified based on their neurologic exams as focal objective, focal subjective, or nonfocal. Outcomes of final diagnoses of acute ischemic stroke and large vessel occlusions were compared across groups. Comparisons were made to other large vessel occlusion prediction scales. RESULTS: Of 521 patients, 342 (65.6%) were categorized as focal objective, 142 (27.2%) as focal subjective, and 37 (7.1%) as nonfocal. Ischemic stroke and large vessel occlusions were diagnosed in 114 (21.9%) and 27 (5.2%) of patients, respectively. Classification as focal objective significantly predicted stroke (odds ratio 3.77; 95% confidence interval 2.17-6.55) and captured all large vessel occlusions (P = .0001). The focal objective categorization was the only tool which achieved 100% sensitivity for large vessel occlusions (with a specificity of 36%) compared to other large vessel occlusion prediction tools. CONCLUSIONS: Patients who presented as stroke alerts without focal neurologic symptoms were unlikely to have large vessel occlusions. With high sensitivity, classifying patients' neurologic exams into focal objective versus subjective or nonfocal categories may serve as a useful tool to screen for large vessel occlusions and prevent unnecessary emergent workup in patients unlikely to be endovascular candidates.


Subject(s)
Brain Ischemia/etiology , Cerebral Arterial Diseases/diagnosis , Disability Evaluation , Neurologic Examination , Stroke/etiology , Adult , Aged , Aged, 80 and over , Brain Ischemia/diagnosis , Brain Ischemia/physiopathology , Brain Ischemia/therapy , Cerebral Arterial Diseases/complications , Cerebral Arterial Diseases/physiopathology , Cerebral Arterial Diseases/therapy , Clinical Decision-Making , Female , Humans , Male , Middle Aged , Predictive Value of Tests , Prognosis , Reproducibility of Results , Retrospective Studies , Severity of Illness Index , Stroke/diagnosis , Stroke/physiopathology , Stroke/therapy , Young Adult
19.
Int J Stroke ; 14(1): 32-43, 2019 01.
Article in English | MEDLINE | ID: mdl-30079825

ABSTRACT

This review will discuss important developments in childhood arterial ischemic stroke over the past decade, focusing on improved understanding of the causes, consequences, and targets for intervention. Risk factors for childhood arterial ischemic stroke are different to adults. Infections, particularly herpes group viruses, are important precipitants for stroke. Non-atherosclerotic arteriopathies are the most common cause of childhood arterial ischemic stroke and an important predictor of recurrent events. Recent advances include the identification of serum biomarkers for inflammation and endothelial injury, and imaging biomarkers to monitor for vascular progression. Multicenter trials of immunotherapies in focal cerebral arteriopathies are currently in development. Recognition of clinical and radiological phenotypic patterns has facilitated the discovery of multisystem disorders associated with arterial ischemic stroke including ACTA2 arteriopathy and adenosine deaminase 2 deficiency. Identification of these Mendelian disorders provide insights into genetic mechanisms of disease and have implications for medical and surgical management. In contrast to adults, there are long diagnostic delays in childhood arterial ischemic stroke. Refinement of pediatric Code Stroke protocols and clinical decision support tools are essential to improve diagnostic certainty and improve access to reperfusion therapies. Children do not recover better than adults following arterial ischemic stroke, with more than half of survivors having long-term impairments. The physical, cognitive, and behavioral consequences of childhood arterial ischemic stroke are increasingly reported but further research is required to understand their impact on participation, quality of life, psychosocial, and family functioning. Longitudinal studies and the use of advanced imaging techniques, to understand neurobiological correlates of functional reorganization, are essential to developing targeted intervention strategies to facilitate recovery.


Subject(s)
Brain Ischemia/therapy , Cerebral Arterial Diseases/therapy , Endothelium, Vascular/immunology , Stroke/therapy , Actins/genetics , Adenosine Deaminase/genetics , Biomarkers , Brain Ischemia/genetics , Cerebral Arterial Diseases/genetics , Child , Genetic Predisposition to Disease , Humans , Inflammation , Intercellular Signaling Peptides and Proteins/genetics , Risk Factors , Stroke/genetics
20.
Br J Neurosurg ; 33(1): 92-93, 2019 Feb.
Article in English | MEDLINE | ID: mdl-28436277

ABSTRACT

Acute concomitant occlusions of the extracranial internal carotid artery and intracranial vessels frequently require multiple passes with stent-retrievers for mechanical thrombectomy. Due to the large clot burden associated with these occlusions, their response to intravenous thrombolysis is poor. We herein report a successful case of evacuating a massive clot (>14 cm) in a single-pass using a stent-retrieval device.


Subject(s)
Arterial Occlusive Diseases/therapy , Carotid Artery, Internal , Carotid Stenosis/therapy , Cerebral Arterial Diseases/therapy , Mechanical Thrombolysis/methods , Carotid Stenosis/surgery , Endovascular Procedures/instrumentation , Endovascular Procedures/methods , Humans , Male , Middle Aged , Stents , Stroke/therapy , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...